Perth biotechs Avicena Systems and Syngenis Laboratories are teaming up to fast-track high-volume pathogen detection technology aimed at protecting Australia’s agriculture, trade and health systems.

Syngenis Laboratories chief technology officer and founder Prof Rakesh Veedu, with AI strategist James Hill, reviewing the AI model. Australia’s biotechnology sector is rapidly colliding with the explosive rise of artificial intelligence and Perth-based Syngenis Laboratories is aiming to plant itself right at the centre of the revolution. The company has built an AI-powered discovery platform, dubbed Syngenis Discovery, designed to dramatically accelerate the hunt for n

Professor Bu Yeap, Clinical Lead, Professor Rakesh Veedu Founder and CTO, Syngenis, Mr David Schwartz, Director, Progenis, Dr Vinod Vathipadiekal, Chief Scientific Officer, Progenis. GLP-1 receptor agonists, the science behind Ozempic and its cousins, have become one of the most talked-about medical breakthroughs of the past decade, reshaping how the world thinks about diabetes and obesity. The numbers are extraordinary, the headlines relentless and the share prices of th

Syngenis Laboratories Founder, Chief Technology Officer and Board Member, Professor Rakesh Veedu, pictured with one of the company’s oligonucleotide synthesisers. Credit: File There is a word almost nobody outside a laboratory will ever use in conversation that many say could play a major role in the future of medicine. You couldn’t spell it after a few drinks, you’ve likely never actually heard of it and yet chances are you have already encountered one of its most practical